Completed PHASE1 INTERVENTIONAL 5-arm NCT07123376

Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy Subjects

A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Study Was Conducted to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of HRS-9231 Injection in a Single Dose in Healthy Chinese Subjects

Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd

Conditions Healthy Volunteers

Interventions HRS-9231 Placebo

Updated 1 time since 2025 Last updated: Aug 8, 2025 Started: Jun 5, 2024 Primary completion: Oct 6, 2024 Completion: Oct 6, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07123376, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd, it has been updated 1 time since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

1 version recorded

Completed — PHASE1 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Shengdi Pharmaceutical Co., Ltd

Data source: Shanghai Shengdi Pharmaceutical Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Suzhou, China